![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ERVMER34-1 |
Gene summary for ERVMER34-1 |
![]() |
Gene information | Species | Human | Gene symbol | ERVMER34-1 | Gene ID | 100288413 |
Gene name | endogenous retrovirus group MER34 member 1, envelope | |
Gene Alias | HEMO | |
Cytomap | 4q12 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H9K5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
100288413 | ERVMER34-1 | P2T-E | Human | Esophagus | ESCC | 4.96e-10 | 1.95e-01 | 0.1177 |
100288413 | ERVMER34-1 | P4T-E | Human | Esophagus | ESCC | 2.00e-13 | 3.93e-01 | 0.1323 |
100288413 | ERVMER34-1 | P5T-E | Human | Esophagus | ESCC | 4.98e-11 | 2.68e-01 | 0.1327 |
100288413 | ERVMER34-1 | P9T-E | Human | Esophagus | ESCC | 2.21e-03 | 1.05e-01 | 0.1131 |
100288413 | ERVMER34-1 | P11T-E | Human | Esophagus | ESCC | 4.63e-02 | 2.20e-01 | 0.1426 |
100288413 | ERVMER34-1 | P16T-E | Human | Esophagus | ESCC | 8.44e-03 | 8.52e-02 | 0.1153 |
100288413 | ERVMER34-1 | P17T-E | Human | Esophagus | ESCC | 1.52e-03 | 3.13e-01 | 0.1278 |
100288413 | ERVMER34-1 | P21T-E | Human | Esophagus | ESCC | 2.11e-02 | 8.92e-02 | 0.1617 |
100288413 | ERVMER34-1 | P24T-E | Human | Esophagus | ESCC | 1.99e-06 | 2.07e-01 | 0.1287 |
100288413 | ERVMER34-1 | P26T-E | Human | Esophagus | ESCC | 7.95e-03 | 1.52e-01 | 0.1276 |
100288413 | ERVMER34-1 | P27T-E | Human | Esophagus | ESCC | 1.00e-04 | 1.44e-01 | 0.1055 |
100288413 | ERVMER34-1 | P28T-E | Human | Esophagus | ESCC | 1.79e-11 | 3.27e-01 | 0.1149 |
100288413 | ERVMER34-1 | P30T-E | Human | Esophagus | ESCC | 3.00e-02 | 1.99e-01 | 0.137 |
100288413 | ERVMER34-1 | P32T-E | Human | Esophagus | ESCC | 3.46e-05 | 2.70e-01 | 0.1666 |
100288413 | ERVMER34-1 | P36T-E | Human | Esophagus | ESCC | 9.99e-06 | 1.72e-01 | 0.1187 |
100288413 | ERVMER34-1 | P37T-E | Human | Esophagus | ESCC | 2.28e-19 | 5.40e-01 | 0.1371 |
100288413 | ERVMER34-1 | P39T-E | Human | Esophagus | ESCC | 7.36e-06 | 1.64e-01 | 0.0894 |
100288413 | ERVMER34-1 | P48T-E | Human | Esophagus | ESCC | 7.08e-03 | 9.34e-02 | 0.0959 |
100288413 | ERVMER34-1 | P52T-E | Human | Esophagus | ESCC | 4.59e-05 | 1.99e-01 | 0.1555 |
100288413 | ERVMER34-1 | P54T-E | Human | Esophagus | ESCC | 3.51e-05 | 9.93e-02 | 0.0975 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERVMER34-1 | SNV | Missense_Mutation | novel | c.1598N>T | p.Ser533Leu | p.S533L | Q9H9K5 | protein_coding | deleterious_low_confidence(0) | benign(0.005) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ERVMER34-1 | SNV | Missense_Mutation | c.1279N>C | p.Asp427His | p.D427H | Q9H9K5 | protein_coding | deleterious_low_confidence(0) | benign(0.062) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ERVMER34-1 | SNV | Missense_Mutation | novel | c.1650G>C | p.Met550Ile | p.M550I | Q9H9K5 | protein_coding | deleterious_low_confidence(0) | benign(0.009) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ERVMER34-1 | SNV | Missense_Mutation | novel | c.872C>T | p.Ser291Phe | p.S291F | Q9H9K5 | protein_coding | tolerated_low_confidence(0.08) | benign(0.003) | TCGA-E2-A15I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ERVMER34-1 | SNV | Missense_Mutation | c.1367N>A | p.Ser456Tyr | p.S456Y | Q9H9K5 | protein_coding | tolerated(0.07) | benign(0.028) | TCGA-E9-A1NE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
ERVMER34-1 | SNV | Missense_Mutation | rs767867286 | c.523A>G | p.Thr175Ala | p.T175A | Q9H9K5 | protein_coding | tolerated_low_confidence(0.19) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ERVMER34-1 | SNV | Missense_Mutation | c.160N>A | p.Glu54Lys | p.E54K | Q9H9K5 | protein_coding | tolerated_low_confidence(0.13) | benign(0.009) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ERVMER34-1 | SNV | Missense_Mutation | novel | c.560N>G | p.Phe187Cys | p.F187C | Q9H9K5 | protein_coding | tolerated_low_confidence(0.14) | benign(0.283) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERVMER34-1 | SNV | Missense_Mutation | novel | c.1601N>T | p.Ala534Val | p.A534V | Q9H9K5 | protein_coding | deleterious_low_confidence(0.03) | benign(0.098) | TCGA-AJ-A2QK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
ERVMER34-1 | SNV | Missense_Mutation | novel | c.80N>C | p.Leu27Pro | p.L27P | Q9H9K5 | protein_coding | deleterious_low_confidence(0.04) | benign(0.003) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |